The Allyl Iodide market is first divided by type, which distinguishes product specifications that directly affect pricing and end‑use suitability. Technical‑grade Allyl Iodide, typically supplied as a bulk liquid with purity levels of 95‑98%, dominates volume‑based sales because it meets the cost constraints of large‑scale flavor, fragrance, and agrochemical manufacturers. Pharma‑grade Allyl Iodide, on the other hand, is produced under stricter GMP conditions, achieving >99.5% purity and often supplied as a stabilized solid or azeotropic mixture to mitigate volatility. Although its unit price is substantially higher, pharma‑grade accounts for a disproportionate share of revenue due to the premium margins in pharmaceutical intermediate synthesis. A secondary distinction between liquid and solid forms further refines demand: liquid forms are preferred for continuous processing streams, while solid forms facilitate precise dosing in batch reactions. Collectively, these type sub‑segments define the supply chain architecture and explain variance in market size, with technical‑grade contributing roughly 70% of total volume and pharma‑grade delivering about 30% of overall revenue.